GAMMA Investing LLC Grows Holdings in ICON Public Limited (NASDAQ:ICLR)

GAMMA Investing LLC increased its stake in ICON Public Limited (NASDAQ:ICLR) by 64.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 433 shares of the medical research company’s stock after buying an additional 169 shares during the period. GAMMA Investing LLC’s holdings in ICON Public were worth $91,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ICLR. Ashton Thomas Private Wealth LLC acquired a new position in ICON Public during the 2nd quarter worth $54,000. EverSource Wealth Advisors LLC lifted its position in shares of ICON Public by 39.2% during the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after purchasing an additional 111 shares during the last quarter. Sara Bay Financial acquired a new position in ICON Public in the third quarter worth about $1,143,000. Whittier Trust Co. increased its holdings in ICON Public by 12.3% in the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after buying an additional 441 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after buying an additional 96 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ICLR. Barclays lowered their price target on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. StockNews.com downgraded shares of ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Citigroup lowered their price objective on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, TD Cowen cut their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Trading Down 0.5 %

Shares of ICLR stock opened at $218.22 on Friday. ICON Public Limited has a 1 year low of $183.38 and a 1 year high of $347.72. The firm has a market capitalization of $18.00 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. The stock has a fifty day moving average of $211.33 and a two-hundred day moving average of $271.77. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $3.10 EPS. As a group, research analysts expect that ICON Public Limited will post 13.42 EPS for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.